New DiviTum(R) TKa Data to be Presented at ASCO in Three Cancer Types

About this update from Biovica International Ab Class B

[{"type":"text","content":"UPPSALA, SE / ACCESS Newswire / May 23, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest cancer meeting, the American Society of Clinical Oncology (ASCO), May 30 - June 3, 2025. ASCO is the world's largest and most influential oncology conference, bringing together approximately 31,000 oncology professionals.","length":504,"tagName":"p"},{"type":"text","content":"The new data further validates DiviTum TKa as a predictive biomarker across three cancer indications:","length":101,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients treated with CDK4/6 inhibitors in the high-profile PEARL study","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"BRAF V600-mutated metastatic melanoma treated with Immune Checkpoint Inhibitors (ICI)","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"Ovarian cancer treated with platinum-based chemotherapy","length":55,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":274,"olType":false},{"type":"text","content":"While the PEARL study represents a large-scale trial that addresses a key clinical decision-making challenge in MBC - whether to select newer versus established treatment combinations - the studies in melanoma and ovarian cancer are more exploratory in nature.","length":260,"tagName":"p"},{"type":"text","content":"" It is exciting that DiviTum TKa will be presented to such a large audience as a predictive biomarker for personalized treatment selection in MBC, malignant melanoma , and ovarian cancer, thereby significantly extending the number of patients who can benefit from DiviTum TKa. Equally exciting, that DiviTum TKa can also predict outcomes for patients receiving the new generation Immune Checkpoint Inhibitors for malignant melanoma," said Anders Rylander, CEO of Biovica.","length":482,"tagName":"p"},{"type":"text","content":"Thank you to the long list of partners in eight European countries, who have contributed to bringing about new knowledge.","length":121,"tagName":"p"},{"type":"text","content":"More about the","length":14,"tagName":"p"},{"type":"table","hea...

More updates from Biovica International Ab Class B